- Home
- BRBR vs MRNA Comparison
BRBR vs MRNA Comparison
Compare BRBR & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRBR
- MRNA
- Stock Information
- Founded
- BRBR 2019
- MRNA 2010
- Country
- BRBR United States
- MRNA United States
- Employees
- BRBR N/A
- MRNA N/A
- Industry
- BRBR Packaged Foods
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BRBR Consumer Staples
- MRNA Health Care
- Exchange
- BRBR Nasdaq
- MRNA Nasdaq
- Market Cap
- BRBR 8.8B
- MRNA 10.6B
- IPO Year
- BRBR 2019
- MRNA 2018
- Fundamental
- Price
- BRBR $62.96
- MRNA $26.56
- Analyst Decision
- BRBR Strong Buy
- MRNA Hold
- Analyst Count
- BRBR 18
- MRNA 19
- Target Price
- BRBR $77.56
- MRNA $48.13
- AVG Volume (30 Days)
- BRBR 2.8M
- MRNA 14.2M
- Earning Date
- BRBR 05-05-2025
- MRNA 05-01-2025
- Dividend Yield
- BRBR N/A
- MRNA N/A
- EPS Growth
- BRBR 49.75
- MRNA N/A
- EPS
- BRBR 2.14
- MRNA N/A
- Revenue
- BRBR $2,192,100,000.00
- MRNA $3,177,000,000.00
- Revenue This Year
- BRBR $17.77
- MRNA N/A
- Revenue Next Year
- BRBR $11.06
- MRNA $8.98
- P/E Ratio
- BRBR $29.39
- MRNA N/A
- Revenue Growth
- BRBR 18.91
- MRNA N/A
- 52 Week Low
- BRBR $48.06
- MRNA $23.15
- 52 Week High
- BRBR $80.67
- MRNA $158.82
- Technical
- Relative Strength Index (RSI)
- BRBR 42.52
- MRNA 50.60
- Support Level
- BRBR $60.09
- MRNA $25.22
- Resistance Level
- BRBR $63.84
- MRNA $27.15
- Average True Range (ATR)
- BRBR 2.07
- MRNA 1.61
- MACD
- BRBR -0.02
- MRNA 0.26
- Stochastic Oscillator
- BRBR 45.48
- MRNA 47.66
About BRBR BellRing Brands Inc.
BellRing Brands Inc is a United States-based company engaged in providing nutrition-related products. Its brands, Premier Protein, Dymatize, and PowerBar provides various products including ready-to-drink protein shakes, powders and nutrition bars. The company's products are distributed through a diverse network of channels including club, food, drug and mass, eCommerce, convenience and specialty.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.